Do analysts rate TSTL or SPEC?

INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts plainly believe INSPECS Group is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 INSPECS Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is TSTL or SPEC more profitable?

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% INSPECS Group -2.67% -6.07% 0.45%

Do analysts recommend SPEC or BVC?

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher possible upside, equities analysts plainly believe INSPECS Group is more favorable than BATM Advanced Communications. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INSPECS Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 BATM Advanced Communications 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

INSPECS Group (SPEC) Competitors

GBX 94 0.00 (0.00%)

As of 03:52 AM Eastern

Compare

SPEC vs. NIOX, TSTL, EKF, CREO, and BVC

Should you buy INSPECS Group stock or one of its competitors? INSPECS Group's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), EKF Diagnostics (EKF), Creo Medical Group (CREO), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does INSPECS Group compare to NIOX Group?

NIOX Group (LON:NIOX) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

NIOX Group presently has a consensus target price of GBX 86, suggesting a potential upside of 25.84%. INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 36.17%. Given NIOX Group's higher probable upside, analysts plainly believe NIOX Group is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, NIOX Group's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
INSPECS Group	Neutral

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NIOX Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.91	£995.88M	£1.64	41.67
INSPECS Group	£191.70M	0.54	-£4.11M	-£9.40	N/A

NIOX Group has a net margin of 14.37% compared to INSPECS Group's net margin of -2.67%. NIOX Group's return on equity of 10.14% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
INSPECS Group	-2.67%	-6.07%	0.45%

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market.

Summary

NIOX Group beats INSPECS Group on 9 of the 12 factors compared between the two stocks.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

22.5% of Tristel shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 19.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
INSPECS Group	Neutral

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
INSPECS Group	-2.67%	-6.07%	0.45%

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	4.08	£6.54M	£16.24	25.94
INSPECS Group	£191.70M	0.54	-£4.11M	-£9.40	N/A

Tristel has a beta of 0.346, meaning that its stock price is 65% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market.

INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts plainly believe INSPECS Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Tristel beats INSPECS Group on 9 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

EKF Diagnostics currently has a consensus target price of GBX 35, indicating a potential upside of 33.59%. INSPECS Group has a consensus target price of GBX 60, indicating a potential downside of 36.17%. Given EKF Diagnostics' higher probable upside, equities analysts plainly believe EKF Diagnostics is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

EKF Diagnostics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, meaning that its share price is 61% more volatile than the broader market.

In the previous week, EKF Diagnostics had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for INSPECS Group. EKF Diagnostics' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
INSPECS Group	Neutral

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 40.0% of EKF Diagnostics shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

EKF Diagnostics has a net margin of 4.12% compared to INSPECS Group's net margin of -2.67%. EKF Diagnostics' return on equity of 3.01% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
INSPECS Group	-2.67%	-6.07%	0.45%

EKF Diagnostics has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.18	£4.68M	£0.47	55.74
INSPECS Group	£191.70M	0.54	-£4.11M	-£9.40	N/A

Summary

EKF Diagnostics beats INSPECS Group on 11 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Creo Medical Group has a beta of 1.563854, meaning that its share price is 56% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, meaning that its share price is 61% more volatile than the broader market.

In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
Creo Medical Group	Neutral
INSPECS Group	Neutral

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creo Medical Group	£6M	9.96	-£25.04M	£1.00	12.30
INSPECS Group	£191.70M	0.54	-£4.11M	-£9.40	N/A

Creo Medical Group has a net margin of 88.33% compared to INSPECS Group's net margin of -2.67%. Creo Medical Group's return on equity of 9.56% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creo Medical Group	88.33%	9.56%	-20.09%
INSPECS Group	-2.67%	-6.07%	0.45%

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 7.0% of Creo Medical Group shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Creo Medical Group presently has a consensus target price of GBX 40, indicating a potential upside of 225.18%. INSPECS Group has a consensus target price of GBX 60, indicating a potential downside of 36.17%. Given Creo Medical Group's higher possible upside, equities research analysts clearly believe Creo Medical Group is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creo Medical Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Creo Medical Group and INSPECS Group tied by winning 7 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

INSPECS Group (LON:SPEC) and BATM Advanced Communications (LON:BVC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

BATM Advanced Communications has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSPECS Group	£191.70M	0.54	-£4.11M	-£9.40	N/A
BATM Advanced Communications	£123.20M	0.34	-£278.26K	-£4.20	N/A

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher possible upside, equities analysts plainly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
BATM Advanced Communications	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.754, suggesting that its share price is 25% less volatile than the broader market.

INSPECS Group has a net margin of -2.67% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -6.07% beat BATM Advanced Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INSPECS Group	-2.67%	-6.07%	0.45%
BATM Advanced Communications	-14.90%	-22.13%	0.58%

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 14.3% of BATM Advanced Communications shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 31.0% of BATM Advanced Communications shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company	Overall Sentiment
INSPECS Group	Neutral
BATM Advanced Communications	Neutral

Summary

INSPECS Group beats BATM Advanced Communications on 8 of the 14 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPEC vs. The Competition

Export

Metric	INSPECS Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£102.62M	£5.83B	£7.00B	£2.89B
Dividend Yield	2.00%	1.75%	2.56%	6.10%
P/E Ratio	-10.00	26.59	271.55	368.50
Price / Sales	0.54	63.13	603.37	83,338.67
Price / Cash	1.63	33.83	28.87	27.89
Price / Book	0.94	6.10	11.17	7.18
Net Income	-£4.11M	£148.46M	£3.45B	£5.89B
7 Day Performance	-3.09%	1.24%	0.98%	0.72%
1 Month Performance	-4.08%	4.77%	2.30%	3.17%
1 Year Performance	96.65%	9.03%	62.38%	64.34%

INSPECS Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPEC INSPECS Group	0.4533 of 5 stars	GBX 94 flat	GBX 60 -36.2%	+96.7%	£102.62M	£191.70M	N/A	1,673	Gap Down
NIOX NIOX Group	2.5355 of 5 stars	GBX 62.20 -1.6%	GBX 86 +38.3%	-3.2%	£265.99M	£48.70M	37.93	92	Gap Up
TSTL Tristel	N/A	GBX 410 -0.6%	N/A	+17.8%	£197.99M	£49.54M	25.25	208
EKF EKF Diagnostics	1.9903 of 5 stars	GBX 26 +2.0%	GBX 35 +34.6%	-15.1%	£109.63M	£51.56M	55.32	356
CREO Creo Medical Group	N/A	GBX 12.57 -1.4%	GBX 40 +218.3%	-9.8%	£61.94M	£6M	12.57	279

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INSPECS Group (SPEC) Competitors

SPEC vs. NIOX, TSTL, EKF, CREO, and BVC

How does INSPECS Group compare to NIOX Group?

Summary

How does INSPECS Group compare to Tristel?

Summary

How does INSPECS Group compare to EKF Diagnostics?

Summary

How does INSPECS Group compare to Creo Medical Group?

Summary

How does INSPECS Group compare to BATM Advanced Communications?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPEC vs. The Competition

INSPECS Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INSPECS Group (SPEC) Competitors

SPEC vs. NIOX, TSTL, EKF, CREO, and BVC

How does INSPECS Group compare to NIOX Group?

Do analysts recommend NIOX or SPEC?

Does the media prefer NIOX or SPEC?

Do insiders and institutionals hold more shares of NIOX or SPEC?

Which has stronger earnings and valuation, NIOX or SPEC?

Is NIOX or SPEC more profitable?

Which has more risk & volatility, NIOX or SPEC?

Summary

How does INSPECS Group compare to Tristel?

Do insiders & institutionals have more ownership in TSTL or SPEC?

Does the media prefer TSTL or SPEC?

Is TSTL or SPEC more profitable?

Which has stronger valuation & earnings, TSTL or SPEC?

Which has more risk & volatility, TSTL or SPEC?

Do analysts rate TSTL or SPEC?

Summary

How does INSPECS Group compare to EKF Diagnostics?

Do analysts rate EKF or SPEC?

Which has more risk and volatility, EKF or SPEC?

Does the media prefer EKF or SPEC?

Do insiders and institutionals believe in EKF or SPEC?

Is EKF or SPEC more profitable?

Which has higher earnings & valuation, EKF or SPEC?

Summary

How does INSPECS Group compare to Creo Medical Group?

Which has more volatility and risk, CREO or SPEC?

Does the media prefer CREO or SPEC?

Which has preferable valuation & earnings, CREO or SPEC?

Is CREO or SPEC more profitable?

Do insiders & institutionals believe in CREO or SPEC?

Do analysts rate CREO or SPEC?

Summary

How does INSPECS Group compare to BATM Advanced Communications?

Which has preferable earnings & valuation, SPEC or BVC?

Do analysts recommend SPEC or BVC?

Which has more volatility & risk, SPEC or BVC?

Is SPEC or BVC more profitable?

Do insiders and institutionals have more ownership in SPEC or BVC?

Does the media refer more to SPEC or BVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPEC vs. The Competition

INSPECS Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools